Background
Methods
Study design
Study population
Inclusion and exclusion criteria
Donor selection
Group1 (donor1) | Group2 (donor2) | Group3 (donor3) | Group4 (donor4) |
---|---|---|---|
Patient 1 | Patient 2 | Patient 7 | Patient 14 |
Patient 3 | Patient 5 | Patient 8 | Patient 15 |
Patient 4 | Patient 6 | Patient 12 | Patient 18 |
Patient 10 | Patient 9 | Patient 13 | Patient 19 |
Patient 11 | Patient 16 | Patient 17 | Patient 20 |
Groups | Stomach ache score | Diarrhea score | Bloody stool score | Mayo score |
---|---|---|---|---|
Group 1 | 1.80 ± 4.02 | 2.40 ± 1.3 | 1.20 ± 1.64 | 2.80 ± 2.95 |
Group 2 | 3.60 ± 3.91 | 1.80 ± 1.64 | 1.20 ± 3.42 | 3.40 ± 2.88 |
Group 3 | 2.40 ± 2.51 | 3.00 ± 3.00 | 0.60 ± 2.51 | 3.60 ± 3.21 |
Group 4 | 1.50 ± 1.73 | 1.50 ± 1.73 | 0.75 ± 1.50 | 1.75 ± 0.96 |
FMT procedure
Baseline patients’ and healthy donors’ characteristics
Patients | Healthy donors | |
---|---|---|
Sex (male/female) | 20 (11/9) | 4 (4/0) |
Age (years) | 62.50 ± 77.14 | 24.75 ± 0.96 |
Height | 165.00 ± 7.90 | 169.50 ± 6.66 |
Weight | 58.10 ± 9.60 | 62.50 ± 2.89 |
Drugs before treatment | ||
5-ASA | 7 | |
Prednisone (combined with 5-ASA) | 0 | |
Mesalazine suppository | 2 | |
Course of disease (years) | 4.5 (3) | |
ESR (mm/h) | 1.80 ± 2.52 | |
CRP (mg/l) | 1.80 ± 2.52 | |
Colonic mucosal score | 1.80 ± 0.70 | |
Mayo score | 5.00 ± 2.75 |
Clinical index scores
Intestinal flora analysis
16S rRNA-seq analysis
Sample ID | Raw Reads | Combined Raw Tags | Qualified Raw Tags | Effective Base (nt) | Q30(%) | GC(%) | Effective(%) |
---|---|---|---|---|---|---|---|
Healthy 1 | 97,968 | 87,682 | 75,161 | 28,871,200 | 96.67 | 50.96 | 71.22 |
Healthy 1 | 95,320 | 85,873 | 73,759 | 28,455,303 | 96.76 | 51.00 | 72.11 |
Healthy 1 | 99,573 | 89,409 | 75,142 | 29,248,027 | 96.66 | 50.79 | 70.43 |
Healthy 1 | 91,806 | 82,526 | 70,806 | 26,899,361 | 96.66 | 50.79 | 70.83 |
Healthy 2 | 88,237 | 79,622 | 66,615 | 26,326,275 | 96.52 | 52.50 | 71.68 |
Healthy 2 | 92,061 | 82,663 | 70,466 | 27,102,744 | 96.64 | 51.35 | 71.16 |
Healthy 2 | 94,606 | 84,899 | 72,022 | 27,386,297 | 96.53 | 52.06 | 69.92 |
Healthy 2 | 83,508 | 74,456 | 61,895 | 24,076,713 | 96.40 | 52.20 | 69.32 |
Healthy 3 | 97,962 | 86,811 | 69,050 | 25,770,148 | 94.35 | 51.31 | 63.31 |
Healthy 3 | 88,333 | 79,683 | 65,667 | 23,865,511 | 94.86 | 51.37 | 65.25 |
Healthy 3 | 97,891 | 86,659 | 68,235 | 25,726,245 | 94.07 | 51.15 | 62.98 |
Healthy 3 | 94,621 | 83,569 | 65,945 | 24,366,516 | 94.30 | 51.87 | 62.11 |
Healthy 4 | 97,662 | 86,481 | 67,588 | 25,200,871 | 94.21 | 51.56 | 62.19 |
Healthy 4 | 94,153 | 83,751 | 66,134 | 24,357,916 | 94.09 | 51.81 | 62.32 |
Healthy 4 | 86,745 | 77,552 | 62,184 | 22,912,891 | 94.25 | 51.40 | 63.72 |
Healthy 4 | 80,899 | 71,599 | 56,065 | 21,052,071 | 94.23 | 50.96 | 62.33 |
Sample ID | Raw Reads | Combined Raw Tags | Qualified Raw Tags | Effective Bases (nt) | Q30 (%) | GC (%) | Effective(%) |
---|---|---|---|---|---|---|---|
d0-A3 | 93,040 | 88,487 | 79,811 | 30,944,428 | 97.16 | 52.49 | 80.8 |
d0-A5 | 83,603 | 79,229 | 70,709 | 27,506,095 | 97.19 | 51.77 | 78.56 |
d0-A6 | 97,570 | 91,686 | 82,546 | 31,275,447 | 97.18 | 50.58 | 76.69 |
d0-A8 | 86,502 | 81,642 | 73,450 | 27,695,120 | 97.17 | 51.43 | 76.82 |
d0-A10 | 81,604 | 77,275 | 70,049 | 26,399,958 | 97.15 | 51.3 | 78.02 |
d0-A11 | 98,275 | 92,745 | 83,720 | 32,698,787 | 97.13 | 51.45 | 79.48 |
d0-A12 | 85,580 | 77,340 | 60,971 | 22,690,822 | 94.2 | 51.9 | 63.55 |
d0-A14 | 89,314 | 84,745 | 76,866 | 28,211,684 | 97.22 | 52 | 76.51 |
d0-B1 | 91,830 | 87,008 | 76,747 | 30,617,125 | 96.95 | 53.2 | 79.9 |
d0-B2 | 82,081 | 77,921 | 67,290 | 27,251,920 | 96.81 | 54.73 | 77.99 |
d0-B4 | 91,046 | 86,561 | 77,753 | 30,224,143 | 97.1 | 53.54 | 80.6 |
d0-B7 | 88,594 | 83,843 | 72,949 | 28,241,953 | 96.94 | 52.89 | 75.45 |
d0-B9 | 89,766 | 85,407 | 77,936 | 28,937,019 | 97.21 | 51.59 | 78.3 |
d1-A3 | 94,602 | 89,947 | 80,540 | 31,277,847 | 97.13 | 52.55 | 80.08 |
d1-A5 | 88,810 | 83,587 | 75,024 | 29,506,841 | 97.12 | 51.8 | 79.36 |
d1-A6 | 92,458 | 87,430 | 78,588 | 30,928,414 | 97.13 | 51.74 | 80.44 |
d1-A8 | 88,997 | 83,816 | 74,889 | 28,211,660 | 97.14 | 51.58 | 75.6 |
d1-A10 | 95,021 | 89,688 | 80,983 | 30,012,662 | 97.09 | 51.25 | 76.24 |
d1-A11 | 88,286 | 83,310 | 75,278 | 28,145,749 | 97.16 | 51.5 | 76.35 |
d1-A12 | 97,742 | 88,876 | 68,748 | 26,725,630 | 94.22 | 53.22 | 65.16 |
d1-A13 | 86,350 | 81,399 | 72,066 | 27,885,218 | 97.04 | 52.02 | 76.87 |
d1-B1 | 84,009 | 79,994 | 72,638 | 27,442,698 | 97.22 | 52.26 | 79.48 |
d1-B2 | 92,523 | 88,004 | 76,896 | 31,318,550 | 96.88 | 54.09 | 79.79 |
d1-B4 | 99,557 | 94,523 | 83,760 | 33,197,434 | 97.05 | 52.82 | 79.67 |
d1-B7 | 81,447 | 76,527 | 68,433 | 25,102,970 | 97.1 | 51.84 | 73.74 |
d1-B9 | 85,819 | 81,046 | 72,942 | 28,034,477 | 97.07 | 51.26 | 78.23 |
d2-A8 | 86,695 | 82,017 | 73,730 | 26,868,038 | 97.15 | 52.25 | 74.5 |
d2-A12 | 82,621 | 78,323 | 69,553 | 26,127,370 | 97.04 | 51.21 | 75.78 |
d2-B2 | 85,964 | 81,497 | 71,186 | 28,547,029 | 96.92 | 53.42 | 78.78 |
d2-B7 | 81,000 | 76,000 | 67,820 | 24,654,602 | 97.05 | 51.4 | 72.8 |
Statistical analysis
Results
Patient characteristics
Clinical outcomes
Time | Diarrhea score | Stomach ache score | Bloody stool score |
---|---|---|---|
Before treatment | 3.75 ± 3.49 | 2.55 ± 2.63 | 3.30 ± 2.36 |
After the first treatment | 2.55 ± 2.63 | 1.80 ± 1.79 | 2.25 ± 2.15* |
After the second treatment | 2.21 ± 2.62 | 1.26 ± 1.52 | 1.74 ± 1.82* |
After the third treatment | 1.42 ± 2.52* | 1.42 ± 1.54* | 0.95 ± 1.43* |
After the forth treatment | 1.26 ± 2.31* | 1.42 ± 1.54* | 1.11 ± 1.49* |
After the fifth treatment | 0.79 ± 1.69* | 0.63 ± 1.26 | 0.79 ± 1.36* |
Time | Colonic mucosal score | Mayo score |
---|---|---|
Before treatment | 1.80 ± 0.70 | 5.00 ± 2.75 |
After the fifth treatment | 1.37 ± 0.60* | 3.00 ± 2.00* |
Time | ESR (mm/h) | CRP (mg/L) |
---|---|---|
Before treatment | 12.17 ± 12.44 | 1.80 ± 2.52 |
After the fifth treatment | 11.63 ± 10.71 | 1.73 ± 2.14 |